| Theme | Colorectal cancer screening and surveillance -- Prospects towards standardization from new findings | |
|---|---|---|
| Title | Research of colorectal cancer screening using total colonoscopy: Prospective Nii-jima and Oshima studies | |
| Publish Date | 2021/05 | |
| Author | Takahisa Matsuda | Cancer Screening Center, National Cancer Center Hospital / Endoscopy Division, National Cancer Center Hospital / Division of Screening Technology, Center for Public Health Sciences, National Cancer Center |
| Author | Yasuo Kakugawa | Cancer Screening Center, National Cancer Center Hospital / Endoscopy Division, National Cancer Center Hospital |
| Author | Kinichi Hotta | Division of Endoscopy, Shizuoka Cancer Center |
| Author | Hiroaki Ikematsu | Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East |
| Author | Masau Sekiguchi | Cancer Screening Center, National Cancer Center Hospital / Endoscopy Division, National Cancer Center Hospital / Division of Screening Technology, Center for Public Health Sciences, National Cancer Center |
| Author | Taku Sakamoto | Endoscopy Division, National Cancer Center Hospital |
| Author | Kenichiro Imai | Division of Endoscopy, Shizuoka Cancer Center |
| Author | Yoshikatsu Koga | Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center |
| Author | Yutaka Saito | Endoscopy Division, National Cancer Center Hospital |
| Author | Nii-jima/Oshima Study Workgroup | |
| [ Summary ] | We outlined two studies on colorectal cancer (CRC) screening using total colonoscopy (TCS). Prior to the start of the Nii-jima study, leaflets highlighting the importance of CRC screening and the specific methods and merits of TCS were distributed to all the study participants 12 times a year to raise awareness. It is speculated that this educational campaign led to a high cumulative participation rate and TCS selection rate. Similar to the Nii-jima study, the Oshima study revealed the high advanced neoplasia detection ability and safety of TCS screening. For the fecal immunochemical test (FIT), the screening sensitivity for invasive cancer was 100 %; however, it decreased to 31.7 % for advanced neoplasia and to 16.7 % for proximal colon. In Japan, TCS has not yet been recommended as a method for population-based screening for CRC; however, data on its effectiveness have been accumulated, and the Akita pop-colon trial demonstrates its safety. We hope that other issues associated with TCS such as quality control, TCS resources, and adherence among others will be cleared, and it will be utilized as the primary screening modality similar to FIT in the future. | |